Guangdong Hengrui Pharmaceutical Co., Ltd

This study tests a new drug, SHR-2173, in 75 adults with primary membranous nephropathy, a kidney disease. The goal is to see if the drug is safe and can help control the disease by reducing protein in the urine. Participants will receive the drug and be monitored for side effect…

This study tests an experimental injection called SHR-1819 in 200 adults with moderate-to-severe atopic dermatitis (a type of eczema). The goal is to see if it safely reduces skin redness, swelling, and itching. Participants will receive either the drug or a placebo, and their pr…

This study tests a new medicine called SHR-1905 for people with severe asthma that is not well controlled by current treatments. About 408 adults will receive either the drug or a placebo to see if it reduces asthma attacks and improves breathing. The goal is to find a safer and …

This early-stage study tests a new drug called SHR-2173 in 10 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The main goal is to see if the drug is safe and tolerable. Researchers will also check if it helps ra…

This study tests a new drug called HRS-9813 in 270 adults with pulmonary fibrosis (IPF or PPF), a condition where lung tissue scars and makes breathing hard. Participants will receive either the drug or a placebo to see if it improves lung function and is safe. The goal is to slo…

This study tests a new medicine called SHR-1703, given as multiple shots under the skin, to see if it is safe and helps control eosinophilic asthma over the long term. About 200 adults with asthma that is not well controlled by standard inhalers will take part. Researchers will t…

This study tests a new drug called SHR-1139 in 20 adults with moderate-to-severe ulcerative colitis, a chronic bowel disease. The treatment has two parts: a 12-week induction phase and a 48-week maintenance phase. The main goal is to see if the drug can improve symptoms by week 1…

This study tests a new medicine called SHR-1703 in 166 adults with EGPA, a rare autoimmune disease that causes inflammation in blood vessels. The goal is to see if the drug can help patients reduce their daily steroid dose and achieve disease remission. Participants must have had…

This study tests an injection called SHR-1819 in 201 teens aged 12 to 17 with severe atopic dermatitis (eczema). The goal is to see if it safely reduces skin redness, itching, and rash better than a placebo. Participants receive the drug or placebo for several weeks, and doctors …

This study tests an injectable drug called SHR-1905 for people with chronic sinusitis and nasal polyps (growths in the nose). It aims to see if the drug can shrink polyps and reduce congestion better than a placebo. About 280 adults who have not responded well to standard nasal s…

This study tests an experimental drug called SHR-2173 for people with active lupus nephritis, a serious kidney complication of lupus. About 51 adults will receive either the drug or a placebo to see if it reduces protein in the urine, a sign of kidney damage. The goal is to contr…

This study tests an experimental drug called SHR-1703 in 400 people aged 12 and older with eosinophilic asthma, a type often hard to control. Participants must already use daily inhaled steroids and another asthma medication. The goal is to see if the drug can reduce the number o…

This study tests an experimental drug called SHR-1905 for adults with moderate-to-severe atopic dermatitis (eczema). About 75 participants will receive either the drug or a placebo injection to see if it safely reduces skin redness, itching, and rash. The main goal is to check if…

This study tests a new medicine called SHR-2173 for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 248 adults will receive either the drug or a placebo to see if it reduces disease activity without serious side effects. The main goal is…

This early-stage study tests whether a new inhaled drug, HRS-9821, is safe and tolerable. It involves 160 participants: healthy volunteers receiving a single dose and COPD patients receiving multiple doses. Researchers will monitor side effects, drug levels in the blood, and hear…

This study tests an experimental injection called SHR-1819 in 100 adults with seasonal allergic rhinitis (hay fever). The goal is to see if it safely reduces daily nasal symptoms like sneezing and congestion. Participants receive either the drug or a placebo, and their symptom sc…

This study tests an experimental drug called SHR-1819, given as an injection, to see if it can safely reduce the intense itching caused by prurigo nodularis—a skin condition with hard, itchy bumps. About 423 adults will receive either the drug or a placebo, and researchers will t…

This study tests how a new experimental drug (HRS-9813) interacts with two approved medicines for pulmonary fibrosis (pirfenidone and nintedanib) in 20 healthy adults aged 18-45. The goal is to measure drug levels in the blood and check for side effects, helping to guide future d…

This early-stage study tests a single injection of a new drug called SHR-3045 in 16 healthy adults. The main goal is to check if it is safe and how the body processes it. This is the first step before testing it in people with rheumatoid arthritis.